Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Topotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 19/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | CASP1 | P29466 | 3/20 | 1.00 |
| ▸ | CASP7 | P55210 | 3/20 | 1.00 |
| ▸ | HBB | P68871 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | KEAP1 | Q14145 | 2/20 | 1.00 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | TOP2A | P11388 | 1/20 | 0.98 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.98 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Topotecan SCHEMBL27326849 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29375999 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL29742318 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL27585549 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10588295 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7247 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL10278 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL418714 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL7056079 | 1.00 | TOP1 (1.00) | TOP1MEN1KMT2ASMN1; SMN2KDM4E | |
| Topotecan SCHEMBL2107916 | 0.99 | TOP1 (0.98) | TOP1MEN1KMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 24850 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-20250281511-A1 | N-(PHENYLSULFONYL)BENZAMIDES AND RELATED COMPOUNDS AS BCL-2 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-09-11 | — | — | US | claimed |
| EP-4594324-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2025-08-06 | — | — | EP | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4591873-A1 | COMBINED THERAPY OF LACTOBACILLUS PLANTARUM STRAIN, AND CANCER TREATMENT METHOD USING SAME | Gi Biome Inc. (KR) | 2025-07-30 | — | — | EP | claimed |
| US-20250222046-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER USING COMBINED THERAPY, COMPRISING LACTOBACILLUS PLANTARUM STRAIN AND ANTICANCER DRUG | GI BIOME INC. (KR) | 2025-07-10 | — | — | US | claimed |
| US-20250215039-A1 | NUCLEOSIDES FOR TREATING CANCER | PRIMEFOUR THERAPEUTICS INC (US) | 2025-07-03 | — | — | US | claimed |
| US-12343352-B2 | N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2025-07-01 | — | — | US | claimed |
| US-20010041713-A1 | Treatment or prevention of prostate cancer with a COX-2 selective inhibiting drug | WALDSTREICHER JOANNE (US) | 2001-11-15 | — | — | US | claimed |
| US-20010039952-A1 | ULTRASOUND ENHANCED CHEMOTHERAPY | WALTER A. HACKER, PH. D | 2001-11-15 | — | — | US | claimed |
| US-6308714-B1 | Ultrasound enhanced chemotherapy | CORAJE, INC. | 2001-10-30 | — | — | US | claimed |
| US-20010018919-A1 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | DIMENSIONAL DOSING SYSTEMS, INCORPORATED | 2001-09-06 | — | — | US | claimed |
| WO-2001060365-A1 | TREATMENT OR PREVENTION OF PROSTATE CANCER WITH A COX-2 SELECTIVE INHIBITING DRUG | MERCK & CO., INC. (US) | 2001-08-23 | — | — | WO | claimed |
| WO-2001054688-A1 | TREATMENT OR PREVENTION OF PROSTATE CANCER WITH A COX-2 SELECTIVE INHIBITING DRUG | MERCK & CO., INC. (US) | 2001-08-02 | — | — | WO | claimed |
| WO-2001052893-A1 | COMPOSITION CONSISTING OF AN ACTIVE INGREDIENT AND A THERAPEUTICALLY ACTIVE DELIVERY SYSTEM, ESPECIALLY IN THE TREATMENT OF ANGIOGENESIS | THERYTE LTD (GB) | 2001-07-26 | — | — | WO | claimed |
| WO-2000020022-A1 | METHODS FOR THE TREATMENT OF CANCER USING CYTOKINES IN COMBINATION WITH LOW LEVEL DOSES OF CHEMOTHERAPY AND/OR RADIOTHERAPY | LT TECHNOLOGY COMPANY, LLC. (US) | 2000-04-13 | — | — | WO | claimed |
| WO-1999038992-A9 | SYNERGISM BETWEEN THYMIDINE KINASE GENE THERAPY AND TOPOISOMERASE I AND TOPOISOMERASE II INHIBITORS | BAYLOR COLLEGE MEDICINE (US) | 1999-10-21 | — | — | WO | claimed |
| WO-1999038992-A1 | SYNERGISM BETWEEN THYMIDINE KINASE GENE THERAPY AND TOPOISOMERASE I AND TOPOISOMERASE II INHIBITORS | BAYLOR COLLEGE OF MEDICINE (US) | 1999-08-05 | — | — | WO | claimed |